Browsing: HCP Access Only 1

Fapon and Halodoc Forge Strategic Partnership to Drive the Development of Indonesia’s In-Vitro Diagnostics Industry

By 0
On October 12th, 2023, Fapon, a leading life-science organization, signed a strategic cooperation agreement with Halodoc, the largest telehealth platform in Indonesia. This partnership brings together Fapon’s expertise in in-vitro diagnostics (IVD) technologies and integrated solutions with Halodoc’s strong sales channels and local service provisions. The partnership aims to enhance the healthcare standards in Indonesia, benefit local communities, and propel the country’s IVD industry.

Log In or Register as a healthcare professional to read the full article.

New adverse event signal – Glucagon-like Peptide-1 Receptor Agonists and Suicidality

By 0
The use of glucagon-like peptide-1 receptor agonists (GLP-1 RA) have increased significantly in recent years due to its marked efficacy in body weight reduction in clinical trials and most recently, due to claims by celebrities and social media personalities that they have lost weight after using Ozempic (Semaglutide). While there were earlier concerns on supply shortage due to high demand of on-label and off-label use, there has been reports of a new adverse event signal that has drawn scrutiny from health authorities in the United States (US), European union (EU) and in Asia about its possible link to suicidal episodes. 

Log In or Register as a healthcare professional to read the full article.

Intravenous Iron In Ambulant Patients With Heart Failure – Do We See The Same Benefits?

By 0
Iron deficiency is present in 50% of the patients with heart failure and it is associated with worse symptoms and outcomes [1]. There have been a few studies analysing the benefit of intravenous (IV) ferric carboxymaltose in heart failure with iron deficiency. In the AFFIRM-AHF [2] trial, administration of IV ferric carboxymaltose reduced the risk of cardiovascular death and total hospitalisations for heart failure in patients hospitalized for acute heart failure.

Log In or Register as a healthcare professional to read the full article.

AstraZeneca And Institute Kanser Negara Partner to Introduce AI Technology For Lung Screening

By 0
In conjunction with Institut Kanser Negara’s (IKN) 10th anniversary, AstraZeneca announced its collaboration to accelerate digitalisation in healthcare by introducing Artificial Intelligence (AI) x-ray technology into early lung screening at government clinics and hospitals under the Projek Saringan Awal Paru-Paru (SAPU) programme. As a centre of excellence for cancer care in the country, IKN will be the first government institution in the country to implement this AI technology.

Log In or Register as a healthcare professional to read the full article.